Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/12/22
Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/06/22
Protalix BioTherapeutics Inc. (PLX) CEO Dror Bashan on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/15/22
Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business ResultsPRNewsWire • 08/15/22
Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022PRNewsWire • 08/08/22
Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of DirectorsPRNewsWire • 06/30/22
Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry DiseasePRNewsWire • 05/26/22
Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/16/22
Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business ResultsPRNewsWire • 05/16/22
Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022PRNewsWire • 05/09/22
Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease TrialBenzinga • 04/04/22
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry DiseasePRNewsWire • 04/04/22
Protalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/31/22
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business ResultsPRNewsWire • 03/31/22
Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022PRNewsWire • 03/24/22
Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry DiseaseBenzinga • 03/18/22
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry DiseasePRNewsWire • 03/18/22
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry DiseasePRNewsWire • 02/27/22
Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/15/21
Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business UpdatePRNewsWire • 11/15/21